DexCom, Inc. (DXCM) has been initiated today with coverage from the research analysts at Feltl & Co. Feltl begins this new coverage of DexCom with an initial price target set at $16.25 dollars and rates performance of ‘DXCM’ as “hold.” Feltl noted their price target is based on valuation of shares and that DexCom’s glucose monitor technology has solid potential.
Shares of DXCM are up during intraday trading, however, unable to break above or below Wednesday’s total daily range at this moment.
An additional note of potential interest to shareholders is that company representatives of DexCom are expected to attend the William Blair’s Growth Stock Conference on June 14th, 2011 this upcoming Tuesday, next week.
DexCom is slated to release their next earnings report on August 3rd, 2011 and is estimated to post negative EPS of 11 cents. Their last earnings report was released on May 3rd, 2011 and announced negative EPS of 19 cents with revenue totaling $14.2 million which was up 49.5 % year to year. DexCom is currently trading below its 50 & 200-day moving averages and 2011 is currently an up year for the company.
DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The company has market capitalization of $871,534,080 and 62,208,000 shares outstanding. DXCM has a 52-week high of $16.91 with the low being $9.60 dollars.